Holen Sie sich die Stockscreener-App
1.69
1.20%
0.02
Handel nachbörslich:
1.72
0.03
+1.78%
Schlusskurs vom Vortag:
$1.67
Offen:
$1.66
24-Stunden-Volumen:
484.36K
Relative Volume:
0.52
Marktkapitalisierung:
$346.79M
Einnahmen:
$889.00K
Nettoeinkommen (Verlust:
$-156.28M
KGV:
-3.2087
EPS:
-0.5267
Netto-Cashflow:
$-150.06M
1W Leistung:
+1.20%
1M Leistung:
+1.81%
6M Leistung:
-23.18%
1J Leistung:
+71.35%
1-Tages-Spanne:
$1.64
$1.72
1-Wochen-Bereich:
$1.61
$1.72
52-Wochen-Spanne:
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.69 | 342.68M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stock - Stock Titan
[Form 3] PROKIDNEY CORP. Initial Statement of Beneficial Ownership - Stock Titan
Identiv And Two Other Penny Stocks To Watch Closely - simplywall.st
PROK: Phase III cell therapy for advanced CKD targets dialysis delay, with pivotal data due in 2027 - TradingView
ProKidney appoints Kenneth Locke as chief technical officer - The Pharma Letter
ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout - The Business Journals
ProKidney expands executive management team with chief technical officer - Winston-Salem Journal
Prokidney Corp. Announces Appointment of Kenneth Locke as Chief Technical Officer - marketscreener.com
ProKidney names Kenneth Locke as chief technical officer By Investing.com - Investing.com Australia
ProKidney Corp. Appoints Kenneth Locke as Chief Technical Officer - geneonline.com
ProKidney names Kenneth Locke as chief technical officer - Investing.com
ProKidney Appoints Kenneth Locke as Chief Technical Officer - The Manila Times
ProKidney shareholders reaffirm board and auditor at 2026 meeting - The Globe and Mail
PROKIDNEY CORP. (PROK) director receives 135,000 stock options grant - Stock Titan
Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation - Stock Titan
ProKidney (PROK) director receives 135,000 stock options grant as compensation - Stock Titan
ProKidney (PROK) director awarded 135K stock options as compensation - Stock Titan
ProKidney (NASDAQ: PROK) grants 135,000 stock options to director - Stock Titan
[Form 4] PROKIDNEY CORP. Insider Trading Activity - Stock Titan
PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award - Stock Titan
ProKidney (NASDAQ: PROK) 2026 meeting backs board nominees and EY - Stock Titan
ProKidney Corp. (PROK) Edges Higher Amid Continued Support: Potential for Breakout Above $1.94 ResistanceHigh Conviction Picks - The Legal Advocate
PROK: Director elections and auditor ratification passed; rilparencel Phase III on track for 2026 - TradingView
ProKidney Corp. (PROK) Jumps Over 7% as Biotech Stock Tests Resistance at $1.90Synthetic Long - The Legal Advocate
Number of shareholders of ProKidney Corp. – NASDAQ:PROK - TradingView
PROK Technical Analysis | Trend, Signals & Chart Patterns | PROKIDNEY CORP (NASDAQ:PROK) - ChartMill
PROK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market - TipRanks
ProKidney's first-quarter loss grows with increased operating expenses - Winston-Salem Journal
BofA Securities Maintains ProKidney(PROK.US) With Sell Rating, Announces Target Price $1 - Moomoo
ProKidney Corp. (PROK) reports Q1 loss, tops revenue estimates - MSN
ProKidney Releases Q1 2026 Financial Results - AlphaStreet
Prokidney Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ProKidney reports Q1 EPS (14c), consensus (14c) - TipRanks
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial - TipRanks
ProKidney Q1 loss widens as R&D spending rises - TradingView
PROKIDNEY CORP. 1Q 2026: Revenue $0.226M, EPS $(0.14) — 10-Q Summary - TradingView
PROK: Phase 3 trial enrollment on track; cash runway extends into mid-2027 amid rising R&D costs - TradingView
ProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial Results - Quiver Quantitative
PROK: Net loss widened to $42.6M in Q1 2026 as R&D spending rose for Phase 3 trials - TradingView
[8-K] PROKIDNEY CORP. Reports Material Event - Stock Titan
ProKidney (NASDAQ: PROK) Q1 2026 loss, R&D spend and cash runway to 2027 - Stock Titan
Kidney disease cell therapy ProKidney eyes key 2027 trial results - Stock Titan
BRIEF-ProKidney Q1 Operating Income USD -44.933 Million - TradingView
Press Release: ProKidney Reports First Quarter 2026 Financial Results and Business Highlights - Moomoo
TradingKey - TradingKey
PROKIDNEY CP (PROK) Eps Diluted (TTM) - Zacks Investment Research
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $600M - Sahm
ProKidney (PROK) to Release Quarterly Earnings on Monday - MarketBeat
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prokidney Corp-Aktie (PROK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):